Cellid Co. Ltd (299660) - Total Liabilities

Latest as of December 2025: ₩36.66 Billion KRW ≈ $24.85 Million USD

Based on the latest financial reports, Cellid Co. Ltd (299660) has total liabilities worth ₩36.66 Billion KRW (≈ $24.85 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Cellid Co. Ltd - Total Liabilities Trend (2015–2025)

This chart illustrates how Cellid Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See Cellid Co. Ltd (299660) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Cellid Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Cellid Co. Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Emami Paper Mills Limited NSE:EMAMIPAP	India	Rs12.83 Billion
Titania Holding AB Series B ST:TITA-B	Sweden	Skr3.70 Billion
Nebag ag SW:NBEN	Switzerland	CHF91.85K
Immutep Ltd AU:IMM	Australia	AU$13.35 Million
GCL Global Holdings Ltd Ordinary Shares NASDAQ:GCL	USA	$123.85 Million
Q.S.I Co. LTD KQ:066310	Korea	₩4.82 Billion
Korea Circuit Co Ltd KO:007815	Korea	₩601.95 Billion
Pharmx Technologies Ltd AU:PHX	Australia	AU$2.90 Million

Liability Composition Analysis (2015–2025)

This chart breaks down Cellid Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cellid Co. Ltd (299660) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.83	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.49	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.33	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cellid Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cellid Co. Ltd (2015–2025)

The table below shows the annual total liabilities of Cellid Co. Ltd from 2015 to 2025.

Year	Total Liabilities	Change
2025-12-31	₩36.66 Billion ≈ $24.85 Million	+47.34%
2024-12-31	₩24.88 Billion ≈ $16.86 Million	+6.22%
2023-12-31	₩23.43 Billion ≈ $15.88 Million	+0.04%
2022-12-31	₩23.42 Billion ≈ $15.87 Million	+20.12%
2021-12-31	₩19.50 Billion ≈ $13.21 Million	+826.53%
2020-12-31	₩2.10 Billion ≈ $1.43 Million	+77.41%
2019-12-31	₩1.19 Billion ≈ $803.76K	+64.58%
2018-12-31	₩720.63 Million ≈ $488.36K	-93.13%
2017-12-31	₩10.49 Billion ≈ $7.11 Million	+161.36%
2016-12-31	₩4.01 Billion ≈ $2.72 Million	+114.39%
2015-12-31	₩1.87 Billion ≈ $1.27 Million	--

About Cellid Co. Ltd

KQ:299660 Korea Biotechnology

Market Cap

$55.18 Million

₩81.43 Billion KRW

Market Cap Rank

#21573 Global

#1255 in Korea

Share Price

₩2760.00

Change (1 day)

+5.34%

52-Week Range

₩2315.00 - ₩5420.00

All Time High

₩127128.20